APPROVED IN CHINA · NOT IN U.S.

Mazdutide

A GLP-1/glucagon dual agonist developed by Eli Lilly and partner Innovent Biologics. Approved in China for chronic weight management. Not approved in the U.S. The first dual agonist to actually launch commercially.

The 30-second read

Mazdutide is a synthetic peptide that activates two hormone receptors at once. GLP-1 (the same receptor as semaglutide) and glucagon (the addition that's distinctive). It was developed by Eli Lilly and licensed in China to Innovent Biologics, which ran the Phase 3 program there. Approved by China's NMPA in 2024/2025 for chronic weight management, mazdutide is the first GLP-1/glucagon dual agonist to actually reach a commercial market. Phase 3 weight-loss numbers in Chinese trials were in the ~14–18% range over 48 weeks. That's meaningful but lower than tirzepatide and retatrutide produced in their Phase 3 programs. Not approved in the U.S. or EU. Eli Lilly's U.S./Western development paths around dual and triple agonists have been concentrated on tirzepatide and retatrutide rather than mazdutide.

Why this peptide is on people's radar

Mazdutide matters mostly because it's the first GLP-1/glucagon dual agonist to actually receive regulatory approval anywhere in the world. While Boehringer's survodutide and Eli Lilly's own retatrutide (which is a triple agonist with glucagon as one of its three targets) work through Phase 3 development in the West, mazdutide already cleared the regulatory bar in China, through Eli Lilly's licensing partnership with Innovent Biologics, who runs Lilly-developed molecules through Chinese clinical and regulatory pathways.

The mechanism story matches the broader dual-agonist narrative: GLP-1 reduces appetite and supports glucose control; adding glucagon-receptor activity raises basal energy expenditure and reduces liver fat. The combined effect, in theory, hits weight loss from both ends, eating less and burning more.

The numbers in Chinese Phase 3 trials are real but moderate by current dual-agonist standards. Mean weight loss in the high-dose arm has been reported in the 14–18% range over 48 weeks, depending on the specific trial and population. That's competitive with semaglutide, less than tirzepatide, well less than retatrutide. The Chinese approval is genuinely an achievement, first-in-class dual-agonist regulatory clearance, without making mazdutide the most clinically impressive option in the dual/triple-agonist class.

For U.S. readers: mazdutide is unlikely to be approved in the U.S. anytime soon. Lilly's U.S. portfolio strategy concentrates on tirzepatide (already approved) and retatrutide (Phase 3, expected approval 2027–28). Mazdutide's commercial story is largely the China market.

What people are usually trying to do with it

People reading about mazdutide are usually following one of these threads:

  • Tracking the global weight-loss-drug landscape
  • Understanding the dual-agonist (GLP-1 + glucagon) mechanism story
  • Following Eli Lilly's broader portfolio strategy (alongside tirzepatide and retatrutide)
  • Considering options if they live in or have access to the Chinese healthcare market
  • Comparing dual agonists to GLP-1 monotherapy and to tirzepatide

What the science actually shows

Mazdutide's clinical data is concentrated in Chinese Phase 3 programs. Plain-English summary:

GLORY Phase 3, chronic weight management

Phase 3 trial in adults in China with overweight or obesity. Reported ~14–18% mean weight loss over 48 weeks at the highest dose, with positive effects on glucose control, liver fat, and metabolic markers. The basis of the Chinese NMPA approval.1

Type 2 diabetes program

Phase 3 trials in adults with T2D have shown A1C improvements alongside weight reduction.2

Mechanism. GLP-1 + glucagon dual agonism

Mazdutide activates GLP-1 receptors (appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion) and glucagon receptors (increased basal energy expenditure, reduced liver fat).3

Liver fat and metabolic markers

The glucagon-receptor component contributes to reductions in hepatic fat content, meaningful for the metabolic-syndrome end of the obesity population.4

What hasn't been demonstrated

FDA approval in the U.S. or EMA approval in Europe. Long-term cardiovascular outcomes data (the trials are accumulating). Direct head-to-head comparison with tirzepatide or retatrutide. Real-world tolerability outside trial conditions.

The honest read

What's solid:

Mazdutide is an actually-approved drug in China, that means a fully completed Phase 3 program, a real regulatory review, and ongoing commercial use. The dual-agonist mechanism is biologically coherent and the trial results support modest improvements over GLP-1 alone for weight loss and metabolic markers.

What's still being worked out:

Whether mazdutide will pursue U.S. or EU approval, and on what timeline. Long-term outcomes data. How it positions commercially against tirzepatide and (if approved) retatrutide.

What's hyped beyond the evidence:

Treating mazdutide as available in the U.S., it isn't. "Compounded mazdutide" being marketed online isn't an FDA-approved drug (mazdutide isn't FDA-approved in the U.S. at all) and isn't operating under any U.S. manufacturing oversight. The Chinese NMPA approval is meaningful in China; it doesn't translate into U.S. clinical-use legitimacy. Also: framing dual-agonist mechanism as automatically better than single-receptor, mazdutide's weight-loss numbers are below tirzepatide, which is itself a dual agonist (GLP-1 + GIP rather than GLP-1 + glucagon). Mechanism complexity isn't always destiny.

Things to know if you're looking into it

  • Approved status: approved by China's NMPA for chronic weight management. Not approved in the U.S. (FDA), EU (EMA), UK, Canada, or other major Western regulatory markets.
  • Innovent partnership: Eli Lilly developed the molecule, with Innovent Biologics as the China partner running clinical and commercial development there. Brand name in China: 玛仕度肽 (Mashiduotai).
  • Mechanism: dual GLP-1 + glucagon receptor agonist. Different mechanism stack than tirzepatide (GLP-1 + GIP) or retatrutide (GLP-1 + GIP + glucagon).
  • How it's used: a once-weekly subcutaneous injection. Dose escalation similar in spirit to other GLP-1 drugs.
  • Side-effect profile: primarily gastrointestinal, nausea, diarrhea, decreased appetite. The glucagon-receptor component adds some considerations around heart rate and blood pressure that are tracked in trials.
  • Not legitimately accessible in the U.S.: any product marketed as "compounded mazdutide" in the U.S. is not the FDA-approved drug (mazdutide isn't FDA-approved here) and isn't subject to the manufacturing oversight that comes with approval anywhere, including in China for the legitimate Innovent product.
  • Specific dosing schedule, mechanism, and trial detail: all in the "Want to go deeper?" section below.

What people often ask

Is mazdutide FDA-approved?

No. Mazdutide is approved in China by the NMPA for chronic weight management. It is not approved by the FDA, EMA, or other major Western regulators.

How does it compare to Zepbound (tirzepatide)?

Mazdutide produced about 14–18% mean weight loss in Chinese Phase 3 trials. Tirzepatide produced about 22.5% in SURMOUNT-1. Different mechanisms (mazdutide is GLP-1 + glucagon, tirzepatide is GLP-1 + GIP). Tirzepatide has produced larger weight-loss numbers in its Western Phase 3 program.

Can I get mazdutide in the U.S.?

Not legitimately. Mazdutide isn't FDA-approved in the U.S. There's no compounding pathway for it (compounding requires an underlying FDA-approved product to base the compound on). Anything sold as "mazdutide" in the U.S. is operating outside any regulatory framework.

Will it come to the U.S.?

Eli Lilly's U.S. portfolio focuses on tirzepatide (already approved) and retatrutide (Phase 3). Mazdutide's commercial story is largely China-focused. Whether Lilly pursues U.S. approval depends on the relative competitiveness of their other products and the strategic case for an additional dual-agonist option.

What's the glucagon-receptor part doing?

Glucagon-receptor activation increases basal energy expenditure (more calories burned at rest) and reduces liver fat. Acutely, glucagon raises blood glucose; chronically, in combination with GLP-1, the net effect is metabolic improvement plus appetite suppression.

What about side effects?

Primarily GI (nausea, diarrhea, decreased appetite). The glucagon-receptor component can affect heart rate and blood pressure, which is tracked carefully in Phase 3.

Does it differ from retatrutide?

Yes. Mazdutide is a dual agonist (GLP-1 + glucagon). Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Retatrutide adds the GIP receptor on top of the same two receptors mazdutide hits, and produces larger weight loss in its Phase 3 trials.

FDA and regulatory status

Status as of May 5, 2026: Approved by China's National Medical Products Administration (NMPA) for chronic weight management in adults. Not FDA-approved (U.S.). Not EMA-approved (EU). Not approved by other major Western regulators. Eli Lilly and Innovent Biologics have additional development programs ongoing for type 2 diabetes and other indications. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, the Innovent / GLORY Phase 3 program, side effects, and references.

Background and development

Mazdutide is a synthetic peptide that activates GLP-1 and glucagon receptors. Originally developed by Eli Lilly under the designation IBI362 / OXM3, the molecule was licensed to Innovent Biologics for clinical and commercial development in China through a strategic partnership. Innovent ran the Phase 3 program in China (the GLORY trials) and obtained NMPA approval for chronic weight management in 2024/2025. Marketed in China under brand name 玛仕度肽 (Mashiduotai).

Mechanism of action

GLP-1 receptor activation

Same receptor as semaglutide. Slows gastric emptying, suppresses appetite via central nervous system effects, stimulates glucose-dependent insulin release, suppresses glucagon release after meals.

Glucagon receptor activation

Glucagon raises blood glucose acutely (which sounds counterintuitive in a weight-loss / diabetes context). However, chronic glucagon-receptor activation also increases basal energy expenditure (more calories burned at rest), reduces liver fat content, and influences fat metabolism. The combined GLP-1 + glucagon signal nets out as glucose-lowering and weight-reducing in trial data.

Half-life and dosing

Plasma half-life supports once-weekly subcutaneous administration.

Approved dosing in China

Approved in China only as of May 2026. Specific dosing schedules vary by indication and are established by prescribers in line with NMPA-approved labeling.

Standard dosing involves a titration schedule from a low starting dose up to the target maintenance dose over weeks, similar in spirit to semaglutide and tirzepatide titrations. Dose escalation manages GI tolerability.

The GLORY Phase 3 program

Innovent's Phase 3 program for mazdutide in China includes:

  • GLORY-1: chronic weight management in adults with overweight or obesity. Reported ~14–18% mean weight loss at the highest dose over 48 weeks.
  • Type 2 diabetes program: separate Phase 3 trials in adults with T2D, with A1C and weight outcomes.
  • Additional indications: trials in metabolic-associated steatotic liver disease (MASLD) and other metabolic conditions are in progress.

Side effects and safety profile

The most common adverse events in the GLORY trials have been gastrointestinal, nausea, diarrhea, vomiting, decreased appetite, comparable to other GLP-1 class drugs. The glucagon-receptor component introduces additional considerations:

  • Modest heart-rate increases observed in some patients
  • Blood pressure tracking in trials
  • Liver enzyme considerations (the glucagon component affects hepatic biology)

Discontinuation rates due to adverse events have been broadly comparable to GLP-1 monotherapy at similar weight-loss-dose levels.

References

  1. Innovent Biologics / Eli Lilly. "GLORY Phase 3 results, mazdutide for chronic weight management." Press releases and regulatory submissions, 2024–2025. Innovent Biologics
  2. Mazdutide type 2 diabetes Phase 3 program. Various Chinese clinical journals and trial registries.
  3. Sánchez-Garrido MA, Brandt SJ, Clemmensen C, et al. (2017). "GLP-1/glucagon receptor co-agonism for treatment of obesity." Diabetologia, 60(10), 1851–1861. PubMed
  4. Zhang H, Wang Y, Zhang X, et al. (2024). "Mazdutide in adults with metabolic dysfunction-associated steatotic liver disease and obesity: pre-specified analyses." The Lancet Diabetes Endocrinol. PubMed
  5. China NMPA. "Mazdutide approval documentation." NMPA.gov.cn
For educational and research purposes only. This is not medical advice. Mazdutide is approved in China for chronic weight management but is not FDA-approved in the United States. There is no legitimate U.S. clinical-use pathway for mazdutide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.